- Policy
- Why Vyndamax and Tabrecta’s reimb were unable to pass DREC
- by Lee, Tak-Sun Jun 15, 2023 05:38am
- i1 The reasons why Vyndamax and Tabrecta, the two drugs that had high reimbursement demand, were unable to pass the Health Insurance Review and Assessment Service’s review were revealed. The two drugs were determined to be ineligible for reimbursement by HIRA’s Drug Reimbursement Evaluation Committee (DREC) at its meeting that was held in
- Policy
- Handok's Imported Monjuvi Licensed
- by Lee, Hye-Kyung Jun 13, 2023 07:39pm
- The Ministry of Food and Drug Safety (Minister Oh Yoo-gyeong) announced on the 9th that it had approved Monjuvi, an orphan drug used to treat diffuse large B-cell lymphoma. For adult patients with relapsed or refractory diffuse large B-cell lymphoma who are unsuitable for autologous hematopoietic stem cell transplantation and who have failed
- Policy
- When will the innovative generic price system be improved?
- by Lee, Tak-Sun Jun 12, 2023 05:42am
- As announced, the government-pharmaceutical working group for PVA improvement plans started on the 1st with the first meeting and got on track. The industry is complaining of frustration as there is no news about the plan for preferential drug prices for innovative new drugs whose working group has already ended or the reorganization of the g
- Policy
- Adtralza is about to be approved in Korea
- by Lee, Hye-Kyung Jun 9, 2023 05:35am
- Domestic product approval for an adult atopic dermatitis treatment developed by LEO Pharma, a Danish pharmaceutical company, is imminent. According to the pharmaceutical industry on the 8th, the Ministry of Food and Drug Safety completed the safety and efficacy review of 'Adtralza 150mg (tralokinumab)', which Leo Pharma applied for. As the
- Policy
- Voluntary price reduction of Diacomit/Olpadine up to↓40%
- by Lee, Hye-Kyung Jun 5, 2023 05:37am
- The drug prices of Diacomit, a treatment for Dravet syndrome, and Olpadine, a treatment for hereditary tyrosinemia, which is a rare essential drug, fell by up to 40%. The KOEDC said in a press release on the 1st, “In the case of Diacomit and Olpadine, insurance prices were voluntarily reduced on April 1 and May 1, respectively.” As a resu
- Policy
- Evrysdi, a tx for Roche's spinal muscular dystrophy, passed
- by Lee, Hye-Kyung Jun 5, 2023 05:37am
- Roche Korea's oral 5q spinal muscular atrophy treatment Evrysdi Dry Syrup has been recognized for its benefits and has crossed the insurance threshold. The HIRA released the results of the '2023 6th Pharmaceutical Reimbursement Evaluation Committee' deliberation on the 1st. Ace Pharma's Megval 50mg and H.I.Pharm's Melpspal 50mg, both of which a
- Policy
- Non-face-to-face demonstration will be alternative relief ?
- by Lee, Jeong-Hwan Jun 5, 2023 05:37am
- While the non-face-to-face treatment pilot project started on the 1st, it is attracting attention that the government will "seek ways to use substitute drugs" as a way to prevent inconvenience caused by the lack of prescription drugs at the pharmacy near the patient after treatment. There is a lot of interest in whether the alternative treat
- Policy
- The method of revaluation of wages that Godex has changed
- by Lee, Tak-Sun Jun 5, 2023 05:36am
- It is noteworthy whether HIRA will act as a variable by changing the evaluation method starting with the re-evaluation of benefit adequacy this year. The improved evaluation method is to increase the objectivity of the social demand part, which is the third evaluation item. Accordingly, in the case of drugs whose clinical usefulness is uncle
- Policy
- Vemlidy IMDs compete with lower price
- by Lee, Tak-Sun May 31, 2023 05:37am
- The latecomers of the hepatitis B treatment Vemlidy that entered the market this year are focusing on their price competitiveness to occupy more shares of the market. Companies that had already reduced their price upon entry are also seemingly holding in check their competitors' prices. According to industry sources on the 29th, Daewoo
- Policy
- Lowest price of dapagliflozin set at 30% of original price
- by Lee, Tak-Sun May 30, 2023 05:33am
- In 2 months after the entry of generics in the market, the price difference between the original diabetes treatment Forxiga Tab (Dapagliflozin propanediol hydrate) and its generics has become one-third. This is because in April last year when many Forxiga generics were listed at once to exceed 20, the insurance price ceiling dropped signi
